Patient characteristics
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 50 (24-67) |
| Male/female | 16/18 |
| Heavy-chain component (%) | |
| IgG | 44.1 |
| IgA | 26.5 |
| Only light chains | 26.5 |
| IgM | 2.9 |
| Light-chain component (%) | |
| κ | 61.8 |
| λ | 38.2 |
| Initial chemotherapy (%) | |
| VBCMP/VBAD | 60.6 |
| Other | 39.4 |
| Autologous transplantation (%) | 76.5 |
| Allogeneic transplantation (%) | 23.5 |
| Chronic GVHD (%) | 62.5 |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 50 (24-67) |
| Male/female | 16/18 |
| Heavy-chain component (%) | |
| IgG | 44.1 |
| IgA | 26.5 |
| Only light chains | 26.5 |
| IgM | 2.9 |
| Light-chain component (%) | |
| κ | 61.8 |
| λ | 38.2 |
| Initial chemotherapy (%) | |
| VBCMP/VBAD | 60.6 |
| Other | 39.4 |
| Autologous transplantation (%) | 76.5 |
| Allogeneic transplantation (%) | 23.5 |
| Chronic GVHD (%) | 62.5 |
VBCMP indicates vincristine, BCNU, cyclophosphamide, melphalan, prednisone; VBAD, vincristine, BCNU doxorubicin, dexamethasone; and GVHD, graft-versus-host disease.